Search

Your search keyword '"Adamts13 activity"' showing total 107 results

Search Constraints

Start Over You searched for: Descriptor "Adamts13 activity" Remove constraint Descriptor: "Adamts13 activity" Topic hematology Remove constraint Topic: hematology
107 results on '"Adamts13 activity"'

Search Results

1. Cost-effectiveness of thrombotic thrombocytopenic purpura diagnosis: a retrospective analysis in the University Hospital Center of Lyon (France)

2. ADAMTS13 testing update: Focus on laboratory aspects of difficult thrombotic thrombocytopenic purpura diagnoses and effects of new therapies

3. Application of the French <scp>TMA</scp> Reference Center Score and the mortality in <scp>TTP Score</scp> in de novo and relapsed episodes of acquired <scp>thrombotic thrombocytopenic purpura</scp> at a tertiary care facility in Spain

4. Diagnosis and follow‐up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay

5. Validation of the PLASMIC score for predicting ADAMTS13 activity <10% in patients with suspected thrombotic thrombocytopenic purpura in Alberta, Canada

6. Absolute Immature Platelet Counts Suggest Platelet Production Suppression during Complicated Relapsing Thrombotic Thrombocytopenic Purpura

7. Insights from the Hereditary Thrombotic Thrombocytopenic Purpura Registry: Discussion of Key Findings Based on Individual Cases from Switzerland

8. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura

9. Clinical presentation and management of acquired thrombotic thrombocytopenic purpura: A case series of 55 patients

10. Evaluation of a rapid turn-over, fully-automated ADAMTS13 activity assay: a method comparison study

11. Platelet factor 4 inhibits ADAMTS13 activity and regulates the multimeric distribution of von Willebrand factor

12. Evaluation of a New, Rapid, Fully Automated Assay for the Measurement of ADAMTS13 Activity

13. Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with ADAMTS13-acquired deficiency in a developing country

14. Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid‐19 patients

15. Inhibitory anti ADAMTS13 antibodies with a new rapid fully automated CLiA assay

16. A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity

17. Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune‐mediated trhrombotic thrombocytopenic purpura

18. Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients

19. The utility of a fast turnaround ADAMTS13 activity in the diagnosis and exclusion of thrombotic thrombocytopenic purpura

20. Treatment of acquired Thrombotic Thrombocytopenic Purpura in the U.S. remains heterogeneous: Current and future points of clinical equipoise

21. Clinical Scoring Systems in Thrombotic Microangiopathies

22. Implementation of a rapid assay of ADAMTS13 activity was associated with improved 30-day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions

23. Comparative Analysis of Clinical Prediction Scores in Acquired Thrombotic Thrombocytopenic Purpura: The Superiority of Plasmic Score

24. ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients

25. The features of acquired thrombotic thrombocytopenic purpura occurring at advanced age

26. A modified PLASMIC score including the lactate dehydrogenase/the upper limit of normal ratio more accurately identifies Chinese thrombotic thrombocytopenic purpura patients than the original PLASMIC score

27. Acute thrombotic thrombocytopenic purpura in Louisiana: Seasonal distribution and evaluation of an ADAMTS13 order screening protocol

28. Real-world data of thrombotic microangiopathy management: The key role of ADAMTS13 activity and complement testing

29. Validation of a panel of ADAMTS13 assays for diagnosis of thrombotic thrombocytopenic purpura: activity, functional inhibitor, and autoantibody test

30. Comparison of low fixed dose versus standard-dose rituximab to treat thrombotic thrombocytopenic purpura in the acute phase and preemptively during remission

31. Ischaemia-reperfusion injury with Pringle's maneuver induces unusually large von Willebrand factor multimers after hepatectomy

32. Early posttransplant plasma ADAMTS13 activity reduction in stem cell transplantation: a prospective study of 46 pediatric patients

33. The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective

35. Effect of ADAMTS13 activity turnaround time on plasma utilization for suspected thrombotic thrombocytopenic purpura

36. ADAMTS13 and von Willebrand factor interactions

37. Rapid ADAMTS13 availability impacts treatment for microangiopathic hemolytic anemia and thrombocytopenia

38. Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases

39. Pregnancy shortly after an acute episode of severe acquired thrombotic thrombocytopenic purpura

40. Evaluation of the Fully Automated HemosIL Acustar ADAMTS13 Activity Assay

41. Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology

42. ASFA CATEGORY IV BECOMES CATEGORY I: IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA IN A PATIENT WITH PRESUMED GEMCITABINE-INDUCED THROMBOTIC MICROANGIOPATHY

43. Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%-20

44. Validation of the PLASMIC score at a University Medical Center

45. Multiple centre evaluation study of ADAMTS13 activity and inhibitor assays

46. Absolute immature platelet count dynamics in diagnosing and monitoring the clinical course of thrombotic thrombocytopenic purpura

47. Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura

48. Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies

49. Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury

50. Severely Deficient ADAMTS13 Activity Predicts Relapse of Immune-Mediated Thrombotic Thrombocytopenic Purpura in Pregnancy

Catalog

Books, media, physical & digital resources